WATERS CORP /DE/

Key metrics

Financial performance

Over the last 9 fiscal years WATERS CORP /DE/'s revenue grew from $2.17B to $3.17B, a compound annual growth rate of 4.3%. Net profit margin compressed from 24.9% to 20.3% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (1,887 filings)

Recent press releases

• Waters Corporation to Present at the Jefferies Global Healthcare Conference2026-05-18

  A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will be available for 90 days.

• Waters Corporation (NYSE: WAT) Reports First Quarter 2026 Financial Results2026-05-05

  _Total reported revenue of $1.267 billion exceeded the high end of the guidance range by $56 million, driven by strong outperformance in both organic revenue and the acquired businesses._

• Waters Corporation Schedules First Quarter 2026 Earnings Conference Call2026-04-20

  Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~16,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide. For more information, please visit www.waters.com/about.

• Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules2026-04-14

  Delivers up to 4x faster chromatographic run times to accelerate decisions across discovery, development, and quality workflows.1,3

• Waters Announces FDA Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay2026-04-08

  FDA-approved BD Onclarity™ HPV Assay is the most comprehensive screening tool for HPV in the U.S.1,4 with extended genotyping and end-to-end automated lab workflows.

Similar companies

The largest companies sharing WATERS CORP /DE/'s SEC industry classification (laboratory analytical instruments).